TSX lower as gold rally takes a breather
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ:NAGE) announced Monday it has increased its full-year 2025 net sales growth forecast to between 25% and 30% year-over-year, up from its previous projection of 22% to 27%. The company has demonstrated strong execution, with revenue growing 35.9% over the last twelve months and maintaining healthy gross margins of 63.6%.
The company, which specializes in NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research, cited recent regulatory developments as potentially beneficial to its business outlook. According to the company, the FDA’s reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN (nicotinamide mononucleotide) could increase awareness of the NAD+ precursor market. While the stock has seen significant volatility recently, dropping 30% in the past week, InvestingPro analysis suggests the stock is currently in oversold territory.
Niagen Bioscience’s core product is Niagen, a patented nicotinamide riboside (NR) supplement designed to boost NAD+ levels. The company manufactures its products in the United States.
"Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience," said Rob Fried, CEO of Niagen Bioscience, in the press release.
The company also noted that its market surveillance program has tested various NAD+ supplements on the market and claims that NMN supplements currently available infringe upon existing patent portfolios related to NMN crystallization.
Niagen Bioscience, formerly known as ChromaDex Corp., collaborates with researchers from various universities and research institutions to study NAD+, a coenzyme found in human cells that decreases with age and exposure to lifestyle stressors.
The company’s announcement comes as part of its ongoing focus on NAD+ science and healthy aging solutions through its consumer supplement brands. InvestingPro data reveals NAGE maintains excellent financial health with an overall score of "GREAT" and holds more cash than debt on its balance sheet. For deeper insights into NAGE’s financial metrics and growth potential, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Niagen Bioscience reported its second-quarter 2025 earnings, which exceeded analysts’ expectations. The company achieved an earnings per share (EPS) of $0.04, doubling the anticipated $0.02. Revenue also surpassed projections, reaching $31.1 million, which is 9.66% higher than expected. H.C. Wainwright responded to these results by raising its price target for Niagen Bioscience from $11 to $12, maintaining a Buy rating on the stock. In addition to financial achievements, Niagen Bioscience announced that its Niagen Plus products, including Niagen IV and injections, are now available at over 900 clinics nationwide. This expansion includes more than 50 iCRYO locations across the U.S., marking a significant distribution milestone for the company’s nicotinamide riboside products. These developments indicate a period of growth and expansion for Niagen Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.